Carmen Criscitiello, MD, PhD

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.

A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.

Recent advances in the characterization and treatment of patients with HER2-positive metastatic breast cancer and brain metastases.

An overview of novel combination regimens being investigated for the treatment of HER2+ metastatic breast cancer.

Recommendations for managing patients with HER2+ metastatic breast cancer who develop interstitial lung disease, an adverse event of trastuzumab deruxtecan.

Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.

Practice-changing data from the DESTINY-Breast03 trial evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer presented at ESMO 2021.

Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.